• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.


Download 2017 Valneva Annual Business Report

August 2, 2018  

Valneva Delivers Strong IXIARO® Sales Growth and Reports Further Progress on Key R&D Programs in H1

Read more    

— Stock information


— July 2, 2018
Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate

Read more 
— Financial Calendar

August 2, 2018
Valneva published its H1 2018 financial results.

Press release
H1 financial report

See all dates


learn more
play video Company Video

– Upcoming conferences

September 7
Goldman Sachs Biotech Symposium, London

October 8-9
European Large & Midcap Event, Paris

October 29-31

World Vaccine Congress Europe, Lisbon

November 13-14
Stifel 2018 Healthcare Conference, New York

Please update your browser...